Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marvel Biosciences Corp (MRVL.VN)

Marvel Biosciences Corp (MRVL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,374
  • Shares Outstanding, K 44,786
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,291 K
  • 60-Month Beta 0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MRVL.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.01 on 06/18/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.095 +26.32%
on 09/19/24
0.130 -7.69%
on 09/10/24
-0.005 (-4.00%)
since 08/30/24
3-Month
0.095 +26.32%
on 09/19/24
0.130 -7.69%
on 09/10/24
unch (unch)
since 07/02/24
52-Week
0.055 +118.18%
on 11/13/23
0.190 -36.84%
on 02/07/24
+0.065 (+118.18%)
since 10/02/23

Most Recent Stories

More News
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome

Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome

Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Closes Private Placement

Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Highlights New Published Research of Its SAB Member Professor David Blum

Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Private Placement Update

Calgary, Alberta--(Newsfile Corp. - June 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), wishes to...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Private Placement

Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)
Marvel Biosciences Announces Testing MB-204 on Autism by French University

Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1200 (-2.12%)
MRVL.VN : 0.120 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with...

See More

Key Turning Points

3rd Resistance Point 0.120
2nd Resistance Point 0.120
1st Resistance Point 0.120
Last Price 0.120
1st Support Level 0.120
2nd Support Level 0.120
3rd Support Level 0.120

See More

52-Week High 0.190
Fibonacci 61.8% 0.138
Fibonacci 50% 0.123
Last Price 0.120
Fibonacci 38.2% 0.107
52-Week Low 0.055

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar